skip to content

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

  •   Table of Contents

Download Guidelines

Management of Medication Toxicity or Intolerance

Gastrointestinal Effects

Last Updated: April 27, 2017; Last Reviewed: April 27, 2017

Table 13c. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects
Adverse Effects Associated ARVs Onset/Clinical Manifestations Estimated Frequency Risk Factors Prevention/Monitoring Management
Nausea/ Vomiting Principally ZDV and PIs, but can occur with all ARVs and COBI Onset:
  • Early
Presentation:
  • Nausea, emesis—may be associated with anorexia and/or abdominal pain
Varies with ARV agent; 10% to 30% in some series Unknown Instruct patient to take PIs with food.

Monitor for weight loss, ARV adherence.
Reassurance—generally improves over time (usually 6–8 weeks)

Supportive care.

Antiemetics may be useful in extreme or persistent cases.
Diarrhea PIs (particularly NFV, LPV/r, FPV/r), buffered ddI, INSTIs (mild) Onset:
  • Early
Presentation:
  • Generally soft, more frequent stools
Varies with ARV agent; 10% to 30% in some series Unknown Monitor for weight loss, dehydration. Exclude infectious causes of diarrhea if prolonged or severe.

Reassurance—generally improves over time (usually 6–8 weeks)

Although treatment data in children are lacking, potentially useful modalities include:
  • Dietary modification
  • Calcium carbonate (should not be used with DTG)
  • Bulk-forming agents (psyllium)
  • Antimotility agents (loperamide)
  • Crofelemer is FDA-approved for treatment of ART-associated diarrhea in adults, but not in children.
Pancreatitis ddI, d4T (especially concurrently), boosted PIs

Reported, albeit rarely, with most ARVs.
Onset:
  • Any time, usually after months of therapy
Presentation:
  • Emesis, abdominal pain, elevated amylase and lipase (asymptomatic hyperamylasemia or elevated lipase do not in and of themselves indicate pancreatitis).
<2% in recent series Use of concomitant medications associated with pancreatitis (e.g., TMP-SMX, pentamidine, ribavirin)

Hypertriglyceridemia

Advanced disease

Previous episode of pancreatitis

Alcohol use
Avoid use of ddI in patients with a history of pancreatitis. Discontinue offending agent—avoid reintroduction.

Manage symptoms of acute episode.

If associated with hypertriglyceridemia, consider interventions to lower TG levels.
Key to Acronyms: ART = antiretroviral therapy; ARV = antiretroviral; COBI = cobicistat; d4T = stavudine; ddI = didanosine; DTG = dolutegravir; FDA = Food and Drug Administration; FPV/r = fosamprenavir/ritonavir; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NFV = nelfinavir; PI = protease inhibitor; RTV = ritonavir; TDF = tenofovir disoproxil fumarate; TG = triglyceride; TMP-SMX = trimethoprim sulfamethoxazole; ZDV = zidovudine

References

  1. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. J Int AIDS Soc. 2010;13:31. Available at http://www.ncbi.nlm.nih.gov/pubmed/20691049.
  2. Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S, Mothi SN, Solomon S. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr. 2009;55(3):155-159. Available at http://www.ncbi.nlm.nih.gov/pubmed/18829638.
  3. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med. 2009;163(2):164-171. Available at http://www.ncbi.nlm.nih.gov/pubmed/19188649.
  4. Hoffmann CJ, Fielding KL, Charalambous S, et al. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS. 2008;22(1):67-74. Available at http://www.ncbi.nlm.nih.gov/pubmed/18090393.
  5. Malan N, Su J, Mancini M, et al. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. AIDS Care. 2010;22(6):677-686. Available at http://www.ncbi.nlm.nih.gov/pubmed/20467943.
  6. Manfredi R, Calza L. HIV infection and the pancreas: risk factors and potential management guidelines. Int J STD AIDS. 2008;19(2):99-105. Available at http://www.ncbi.nlm.nih.gov/pubmed/18334062.
  7. Turner MJ, Angel JB, Woodend K, Giguere P. The efficacy of calcium carbonate in the treatment of protease inhibitor-induced persistent diarrhea in HIV-infected patients. HIV Clin Trials. 2004;5(1):19-24. Available at http://www.ncbi.nlm.nih.gov/pubmed/15002083.
  8. Heiser CR, Ernst JA, Barrett JT, French N, Schutz M, Dube MP. Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea. J Int Assoc Physicians AIDS Care. 2004;3(4):121-129. Available at http://www.ncbi.nlm.nih.gov/pubmed/15768732.
  9. Tukei VJ, Asiimwe A, Maganda A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J Acquir Immune Defic Syndr. 2012;59(3):274-280. Available at http://www.ncbi.nlm.nih.gov/pubmed/22126740.
  10. Wegzyn CM, Fredrick LM, Stubbs RO, Woodward WC, Norton M. Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants. J Int Assoc Physicians AIDS Care (Chic). 2012;11(4):252-259. Available at http://www.ncbi.nlm.nih.gov/pubmed/22544446.
  11. Oumar AA, Diallo K, Dembele JP, et al. Adverse drug reactions to antiretroviral therapy: prospective study in children in sikasso (mali). J Pediatr Pharmacol Ther. 2012;17(4):382-388. Available at http://www.ncbi.nlm.nih.gov/pubmed/23411444.
  12. Wattanutchariya N, Sirisanthana V, Oberdorfer P. Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment. HIV Med. 2013;14(4):226-232. Available at http://www.ncbi.nlm.nih.gov/pubmed/23094820.
  13. Van Dyke RB, Wang L, Williams PL, Pediatric ACTGCT. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198(11):1599-1608. Available at http://www.ncbi.nlm.nih.gov/pubmed/19000014.
  14. Strehlau R, Donati AP, Arce PM, et al. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naive and -experienced infants and children aged >/=3 months to <6 years. J Int AIDS Soc. 2015;18:19467. Available at http://www.ncbi.nlm.nih.gov/pubmed/26066346.
  15. Clay PG, Crutchley RD. Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy. Infect Dis Ther. 2014. Available at http://www.ncbi.nlm.nih.gov/pubmed/25388760.
  16. Gutierrez Mdel M, Mateo MG, Vidal F, Domingo P. Drug safety profile of integrase strand transfer inhibitors. Expert Opin Drug Saf. 2014;13(4):431-445. Available at http://www.ncbi.nlm.nih.gov/pubmed/24597519.
  17. Lee FJ, Carr A. Tolerability of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7(5):422-428. Available at http://www.ncbi.nlm.nih.gov/pubmed/22886031.
  18. Szoke D, Ridolfo A, Valente C, Galli M, Panteghini M. Frequency of pancreatic hyperamylasemia in Human Immunodeficiency Virus-positive patients in the highly active antiretroviral therapy era. Am J Clin Pathol. 2016;145(1):128-133. Available at http://www.ncbi.nlm.nih.gov/pubmed/26712880.
  19. Castro JG, Chin-Beckford N. Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Expert Rev Clin Pharmacol. 2015;8(6):683-690. Available at https://www.ncbi.nlm.nih.gov/pubmed/26517110.
  20. Abadi J, Sprecher E, Rosenberg MG, et al. Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children. J Acquir Immune Defic Syndr. 2006;41(3):298-303. Available at http://www.ncbi.nlm.nih.gov/pubmed/16540930.

Download Guidelines